Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HMPL-004 Maintenance in Ulcerative Colitis
NCT01882764Phase 3Terminated
- Sponsor
- Hutchison MediPharma (HMP)
- Start
- Jun 2013
- Primary completion
- Oct 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in ulcerative colitis (UC) comparing HMPL-004 1800 mg/day with Placebo (2 arms). Primary endpoint: Proportion of Subjects Achieving Clinical Remission at 52 weeks. Started Jun 2013; status: terminated.
02
Drugs
andrographolide
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT01882764.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01882764.